Biological Information
Background Information:
The abl oncogene was initially identified as the viral transforming gene (v-abl) of Abelson murine leukemia virus (A-MuLV), from a chemically thymectomized mouse inoculated with Moloney murine leukemia virus (M-MuLV). The v-abl genome consists of M-MuLV gag sequences fused to mouse c-abl, resulting in the production of phosphoproteins, p160 and p120 gag/c-abl with protein-tyrosine kinase activity, as the major translational products. The abl oncogene is implicated in serval human leukemias including chronic myelocytic (CML), adult acute lymphoblastic (ALL) and pediatric ALL. In these leukemias the c-abl proto-oncogene undergoes a chromosomal translocation producing the Philadelphia (;) chromosome resulting in the fusion of c-abl sequences to the bcr gene of chromosome 22, and the molecular consequences of this translocation is the generation of a chimeric bcr/c-abl mRNA encoding activated abl protein-tyrosine kinase.
Target Class:
Kinase
Family:
TK
Sub Family:
Protein Tyrosine
Protein Name:
Abl
Protein Aliases:
Abelson murine leukemia viral oncogene homolog 1|Abelson tyrosine-protein kinase 1|Proto-oncogene c-Abl|p150
Accession Number:
J02995.1
UniProt Number:
P00520
Gene Name:
Abl1
Gene ID:
11350
Gene Aliases:
JTK7|c-ABL|p150
Target Species:
Mouse
Usage
Product Type:
Enzymes
Application:
Drug Discovery & Development
Storage Conditions:
1 year at -70°C
Usage disclaimer:
These products may be covered by issued US and/or foreign patents, patent applications and subject to a Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.
Assay Information
Assay Type:
Enzymatic
Clinical Relevance
Therapeutic Area:
Oncology/Immuno-Oncology